Head-To-Head Contrast: electroCore (NASDAQ:ECOR) vs. Teleflex (NYSE:TFX)

Teleflex (NYSE:TFX) and electroCore (NASDAQ:ECOR) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

95.6% of Teleflex shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 0.7% of Teleflex shares are held by insiders. Comparatively, 7.8% of electroCore shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Teleflex and electroCore”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99 billion	3.18	-$905.64 million	($23.29)	-6.43
electroCore	$32.03 million	2.37	-$13.97 million	($1.66)	-5.06

electroCore has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Teleflex has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, electroCore has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Teleflex and electroCore, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1	5	5	1	2.50
electroCore	1	1	1	0	2.00

Teleflex currently has a consensus target price of $154.40, suggesting a potential upside of 3.13%. electroCore has a consensus target price of $18.00, suggesting a potential upside of 114.29%. Given electroCore’s higher probable upside, analysts clearly believe electroCore is more favorable than Teleflex.

Profitability

This table compares Teleflex and electroCore’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
electroCore	-39.96%	N/A	-81.35%

Summary

Teleflex beats electroCore on 10 of the 15 factors compared between the two stocks.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

About electroCore

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.